Glycoproteins comprise more than half of current FDA-approved protein cancer markers, but the development of new glycoproteins as disease biomarkers has been stagnant. Here we present a pipeline to develop glycoproteins from extracellular vesicles (EVs) through integrating quantitative glycoproteomics with a novel reverse phase glycoprotein array and then apply it to identify novel biomarkers for breast cancer. EV glycoproteomics show promise in circumventing the problems plaguing current serum/plasma glycoproteomics and allowed us to identify hundreds of glycoproteins that have not been identified in blood. We identified 1,453 unique glycopeptides representing 556 glycoproteins in EVs, among which 20 were verified significantly higher in individual breast cancer patients. We further applied a novel glyco-specific reverse phase protein array to quantify a subset of the candidates. Together, this study demonstrates the great potential of this integrated pipeline for biomarker discovery.
[1]Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.
[2]Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
[3]Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.
[4]Tymora Analyt Operat, W Lafayette, IN 47906 USA.
[5]Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
[6]Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
[7]Purdue Univ, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA.
(8.0+极速模式)